- Home
- VNRX
VNRX
VolitionRX Limited
as 05-30-2025 4:00pm EST
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HENDERSON |
| Market Cap: | 52.4M | IPO Year: | N/A |
| Target Price: | $4.17 | AVG Volume (30 days): | 263.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $0.90 | Next Earning Date: | 05-15-2025 |
| Revenue: | $1,308,361 | Revenue Growth: | 64.16% |
| Revenue Growth (this year): | 563.72% | Revenue Growth (next year): | 160.43% |
Stock Insider Trading Activity of VolitionRX Limited (VNRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Micallef Jacob Vincent | VNRX | Chief Scientific Officer | May 19 '25 | Buy | $0.43 | 50,000 | $21,500.00 | 426,033 | |
| Reynolds Cameron John | VNRX | President and CEO | May 19 '25 | Buy | $0.44 | 20,000 | $8,730.00 | 2,319,222 | |
| Innes Guy Archibald | VNRX | Director | Mar 26 '25 | Buy | $0.55 | 181,818 | $99,999.90 | 868,689 | |
| Reynolds Cameron John | VNRX | President and CEO | Mar 26 '25 | Buy | $0.55 | 181,818 | $99,999.90 | 2,319,222 |
Latest VolitionRX Limited News
VNRX Breaking Stock News: Dive into VNRX Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
4 days ago
VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applications, particularly cancer & sepsis.
PR Newswire
12 days ago
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
GuruFocus.com
15 days ago
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones
Associated Press Finance
16 days ago
VolitionRX: Q1 Earnings Snapshot
PR Newswire
16 days ago
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
GuruFocus.com
16 days ago
VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For
PR Newswire
19 days ago
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
PR Newswire
24 days ago
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
Compare VNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VNRX VolitionRX Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.